Harvard Business Review Argues U.S. Medical Centers Need a New Drug Discovery Model
A new Harvard Business Review piece argues that academic medical centers need to rethink how they approach drug discovery and development. The message is that current structures are too slow and fragmented to capitalize on AI-enabled innovation.
The HBR argument is timely because it points to a structural bottleneck that technology alone cannot solve. U.S. medical centers have deep scientific expertise, but many are not organized to translate that expertise into a repeatable discovery engine.
AI strengthens the case for change because it lowers the cost of hypothesis generation and target prioritization, but it does not remove the need for integrated teams, capital discipline, and decision-making speed. Without a new operating model, medical centers may continue to generate valuable science while leaving translational value on the table.
The most interesting implication is that the institutional winners in AI drug discovery may not be the biggest hospitals or the most famous labs. They may instead be centers that build hybrid models combining academic depth, industry-style execution, and tighter links to commercialization. That would be a meaningful shift in how biomedical innovation is organized.
If medical centers do adapt, they could become much more important partners to biotech and pharma companies seeking early-stage innovation. If they do not, AI may deepen the gap between discovery-rich institutions and those actually capable of converting ideas into medicines.